History and Functional Principle of Rigvir® for Ovarian Cancer
Rigvir® medicine is an integral part of virotherapy. Virotherapy implies treating tumours and metastases with the help of non-pathogenic viruses, and Rigvir® is the first officially recognized. Non-pathogenic virus means that no other disease will appear as a result of Rigvir® injection.
Rigvir® is used to conquer different cancer types, including ovarian.
Rigvir® history has begun in the 1950-60s in Latvia and stretched out through time and borders. Officially, Rigvir® was registered in 2004 (Latvia), and then it was adopted by Georgia in 2015 and Armenia in 2016. Additionally, oncologists from more than 20 states come to Latvia to learn how to implement virotherapy methods.
Why is Rigvir® gaining popularity among international patients? Unlike other common cancer therapies, it doesn’t damage healthy cells of your organism. When you get a Rigvir® injection, the medicine scans your body to detect and destroy the malignant cells. You can use virotherapy for ovarian cancer as the major therapy, or as an additional treatment to radio or chemotherapy.
Side effects of Rigvir® is what most patients are usually concerned about. The major one recorded is an insignificant temperature rise up to 37.5°C/99.5°F that lasted for up to three days. Moreover, only a minority of patients face it, so there’s a chance you’ll face none.
Since 1968 some clinical trials have been conducted to prove Rigvir® healing power. 415 melanoma patients received the treatment, and their survival rates improved. Further clinical experience proved that Rigvir® can treat:
- Ovarian cancer
- Kidney cancer
- Prostate cancer
- Bladder cancer
- Prostate cancer etc.
The latest publication about virotherapy in Melanoma Research, a peer-reviewed medical journal, confirms that survival rates of Rigvir® patients rose in 4-6 times.
You can also conquer the disease with virotherapy for ovarian cancer. Remember that your case is like no others. Therefore, the oncologists should first assess your case at Global Virotherapy Cancer Clinic in Latvia to see whether you qualify for Rigvir® therapy. To do that they will first ask you to provide the following medical documents:
- Cytological findings
- Histopathological findings
- Blood count (including WBC) no older than 2 weeks
- ALT and analysis for creatinine
You’ll get the feedback from the support agent in 2-3 days which are needed for your free case assessment. Regardless of the fact whether you qualify for the Rigvir® therapy or not, you will receive the email with details about your particular situation. Below see more information on the Rigvir ®therapy package.
To know whether you or someone you know can benefit from Rigvir® therapy and what budget to plan, click the button below.
List of References
- Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.
- “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.
- Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.